MEZZADRI, LUCA

MEZZADRI, LUCA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 15 di 15 (tempo di esecuzione: 0.022 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Aspergillus Endocarditis: A Rare but Serious Complication During Treatment With Ibrutinib 01 - Articolo su rivista 2025 Mezzadri, LucaMarchetto, GiovanniLapadula, GiuseppeBonfanti, Paolo +
Ceftazidime-avibactam plus aztreonam versus cefiderocol in the treatment of infections caused by Metallo-β lactamase-Producing Microorganisms: real-word data from the Italian cohort SUSANA 02 - Intervento a convegno 2025 Mezzadri LCorti NBonfanti P. +
Clinical use of dalbavancin in the Italian SUSANA cohort (SUrveillance of SAfety and outcome of New Antibiotics) 01 - Articolo su rivista 2025 Mezzadri, LucaBonfanti, Paolo +
Comparison of meropenem-vaborbactam vs ceftazidime-avibactam in the treatment of KPC producing Klebsiella pneumoniae infections 02 - Intervento a convegno 2025 Mezzadri LCorti NBonfanti P. +
Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy 01 - Articolo su rivista 2025 Mezzadri, LucaMalandrin, SergioMonti, BiancaBonfanti, PaoloLapadula, Giuseppe +
Impact of cefiderocol therapy on patient survival across different multidrugresistant Gram-negative bacilli infections. 02 - Intervento a convegno 2025 N. CortiL. MezzadriP. Bonfanti +
Late-Onset Combined Immunodeficiency presenting with Progressive Multifocal Leukoencephalopathy and associated Immune Reconstitution Inflammatory Syndrome 01 - Articolo su rivista 2025 Mezzadri, LucaLapadula, GiuseppeBonfanti, Paolo +
Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study) 01 - Articolo su rivista 2025 Lapadula, GiuseppeMezzadri, LucaBonfanti, Paolo +
Potential for replacing protease inhibitor with doravirine in cART-experienced subjects successfully treated with darunavir-cobicistat plus dolutegravir dual regimen 02 - Intervento a convegno 2025 LAPADULA, GiuseppeMEZZADRI, LucaBONFANTI, Paolo +
Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study 01 - Articolo su rivista 2024 Lapadula, GiuseppeMezzadri, LucaAntolini, LauraMalandrin, SergioBonfanti, Paolo +
Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infections 02 - Intervento a convegno 2024 Luca MezzadriNicolò CortiPaolo Bonfanti. +
Long-term durability of dolutegravir + darunavir/cobicistat dual regimen in highly antiretroviral-experienced people living with HIV (DoDaco study) 02 - Intervento a convegno 2024 Lapadula, GMezzadri, LBonfanti, P +
Mpox Virus in the Pharynx of Men Having Sex with Men: A Case Series 01 - Articolo su rivista 2024 Lapadula, GMezzadri, LBonfanti, P +
Symptomatic neurocognitive impairmentassociated to CNS viral escape in an HIV-1 infected patient: a case report. 01 - Articolo su rivista 2024 Mezzadri LucaBana Nicholas BrianBonfanti Paolo +
Infezione disseminata da Mycobacterium avium complex con batteriemia persistente in un paziente AIDS-presenter [Disseminated Mycobacterium avium complex infection with persistent bacteremia in an AIDS-presenter patient] 01 - Articolo su rivista 2023 Mezzadri LucaBisi LucaLapadula GiuseppeCarbone MaurizioBonfanti Paolo +